{"entity":{"id":"paper-patasius-lithuania-psa-screening-jcm-2020","kind":"paper","name":"Ten years of Lithuania's population-based PSA early detection programme for prostate cancer","aka":[],"tldr":"In Lithuania's PSA testing programme for men aged 50 to 74, 70% of the men eligible were tested at least once in the first ten years, and men who took part were more likely to be diagnosed while the cancer was still confined to the prostate.","summary":"Published as \"Prostate Cancer Screening with PSA: Ten Years' Experience of Population Based Early Prostate Cancer Detection Programme in Lithuania\". A retrospective analysis of screening activity recorded in 2006 to 2015 among men aged 50 to 74, estimating coverage, cancer detection, compliance with biopsy and positive predictive values in each screening round, inside and outside the target population.","asOf":"2026-11-11","links":[{"label":"J Clin Med 2020","url":"https://doi.org/10.3390/jcm9123826"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/33255919/"}],"tags":[],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["lithuanian-cancer-registry","nci-vilnius"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"Journal of Clinical Medicine","year":2020,"doi":"10.3390/jcm9123826","pmid":"33255919","authors":"Patasius A, Krilaviciute A, Smailyte G.","paperType":"observational","findings":["16,061 prostate cancers were registered within the programme in its first ten years, 10,202 among screened men but reported outside the programme, and 1,455 in men never screened.","Coverage reached up to 45.5% of the target population in recent rounds; 70% of the target population was screened at least once in ten years.","The share of PSA-positive men fell from 16.9% in 2006 to 10.7% in 2014 to 2015; up to 40.0% of PSA-positive men had a biopsy, and 42.0% of biopsies found cancer.","Screening participants were more likely than non-participants to be diagnosed with organ-confined disease."],"whatItMeans":"Lithuania has offered PSA testing through a national programme since 2006; this is an account, from the National Cancer Institute's cancer epidemiology laboratory, of what the programme did in its first decade.","caveats":["The authors describe the screening as unorganised, with low coverage in each round.","The study reports detection and stage, not deaths prevented, and does not measure overdiagnosis."]},"route":"/key-papers/paper-patasius-lithuania-psa-screening-jcm-2020/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"institution":[{"id":"lithuanian-cancer-registry","kind":"institution","name":"Lithuanian Cancer Registry","route":"/institutions/lithuanian-cancer-registry/"},{"id":"lithuania-ministry-of-health","kind":"institution","name":"Ministry of Health of the Republic of Lithuania","route":"/institutions/lithuania-ministry-of-health/"},{"id":"nci-vilnius","kind":"institution","name":"National Cancer Institute, Lithuania","route":"/institutions/nci-vilnius/"}]}}